NCT02802228View on ClinicalTrials.gov

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 6, 2017

Primary Completion Date

July 17, 2018

Study Completion Date

July 17, 2018

Conditions
Portal HypertensionLiver Cirrhosis
Interventions
DRUG

Ifetroban

thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule

DRUG

Placebo

matched placebo delivered as infusion and oral capsule

Trial Locations (6)

23114

Virginia Commonwealth University Medical Center, Richmond

29425

Medical University of South Carolina, Charleston

33606

Tampa General Medical Group, Tampa

43210

The Ohio State University Wexner Medical Center, Columbus

46202

Indiana University, Indianapolis

75246

Baylor University Medical Center, Dallas

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY

NCT02802228 - Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients | Biotech Hunter | Biotech Hunter